Ashley Meakin

Dr. Ashley Meakin

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AMAshley Meakin
Ashley Meakin
JCJames Cuffe
James Cuffe
JDJack R. T. Darby
Jack R. T. Darby
JMJanna Morrison
Janna Morrison
VCVicki Clifton
Vicki Clifton
It is well understood that sex differences exist between females and males even before they are born. These sex-dependent differences may contribute to altered growth and developmental outcomes for the fetus. Based on our initial observations in the human placenta, we hypothesised that the male prioritises growth pathways in order to maximise growth through to adulthood, thereby ensuring the greatest chance of reproductive success. However, this male-specific “evolutionary advantage” likely contributes to males being less adaptable to shifts in the in-utero environment, which then places them at a greater risk for intrauterine morbidities or mortality. Comparatively, females are more adaptable to changes in the in-utero environment at the cost of growth, which may reduce their risk of poor perinatal outcomes. The mechanisms that drive these sex-specific adaptations to a change in the in-utero environment remain unclear, but an increasing body of evidence within the field of developmental biology would suggest that alterations to placental function, as well as the feto-placental hormonal milieu, is an important contributing factor. Herein, we have addressed the current knowledge regarding sex-specific intrauterine growth differences and have examined how certain pregnancy complications may alter these female- and male-specific adaptations.

1 June 2017 in Placenta
Verified
Journal Article
Closed access
AMAshley Meakin
Ashley Meakin
ZSZ. Saif
Z. Saif
AJA.R. Jones
A.R. Jones
PAP.F. Valenzula Aviles
P.F. Valenzula Aviles
VCVicki Clifton
Vicki Clifton

1 May 2019 in Placenta
Verified
Journal Article
Closed access
AMAshley Meakin
Ashley Meakin
ZSZarqa Saif
Zarqa Saif
ATAstrud R. Tuck
Astrud R. Tuck
VCVicki Clifton
Vicki Clifton


1 August 2019 in Placenta
Verified
Journal Article
Closed access
VCVicki Clifton
Vicki Clifton
MMMegan McDonald
Megan McDonald
JMJanna Morrison
Janna Morrison
SHStacey L. Holman
Stacey L. Holman
MLMitchell C Lock
Mitchell C Lock
TMtim moss
tim moss

9 December 2023 in Life Sciences
Verified
Journal Article
Open access
AMAshley Meakin
Ashley Meakin
PNPeter W. Nathanielsz
Peter W. Nathanielsz
CLCun Li
Cun Li
VCVicki L. Clifton
Vicki L. Clifton
MWMichael D. Wiese
Michael D. Wiese
JMJanna Morrison
Janna Morrison
Maternal obesity (MO) increases fetal androgen concentrations, the prevalence of macrosomia, and predisposes offspring to metabolic dysfunction in later life, especially males. These risks may be, in part, the result of increased liver-specific androgen signalling pathway activity in utero. Androgen signalling activity can be suppressed by androgen metabolism via cytochrome P450 (CYP) isoenzymes (CYP2B6, CYP3A) or through inhibition of the full-length androgen receptor (AR-FL) via the antagonistic isoform, AR-45. We hypothesised MO impairs CYP enzyme activity and AR-45 expression in male fetal livers, thereby enhancing activity of androgen signalling pathways. Nine months prior to pregnancy, nulliparous female baboons were assigned to either ad libitum control or high fat diet. At 165 day (d) gestation (term, 180 d) fetal liver was collected (n = 6/sex/group). CYP activity was quantified using functional assays; subcellular AR expression was measured using Western blot. CYP2B6 and CYP3A activity, and nuclear expression of AR-45, was reduced in MO males only. Nuclear AR-45 expression was inversely related with fetal body weight of MO males only. Reduced CYP2B6 and CYP3A activity in conjunction with decreased nuclear AR-45 expression may enhance liver androgen signalling in males from MO pregnancies, thereby increasing the risk of macrosomia, as well as metabolic dysfunction in later life.